Low-density lipoprotein cholesterol (LDL-C) has been extensively evaluated. Prospective cohort studies, randomized controlled trials, biology, pathophysiology, genetics, and Mendelian randomization studies, have clearly taught us that LDL-C causes atherosclerotic cardiovascular disease. The newest class of drugs to lower LDL-C, the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, have been found to safely reduce LDL-C approximately 60% when added to high-intensity statin therapy. Because their cost is much greater than that of the currently available agents, their value has been questioned. In late August, 2017, two groups assessed the value of this class of drugs looking at cost-effectiveness; however, the Institute for Clinical and Economic Review and Fonarow and colleagues found disparate results when assessing PCSK9 valuation. Herein, we review the evolution of LDL-C from hypothesis to fact, and then attempt to adjudicate the 2 models, shedding light on the complex modeling process. We find that models of cost-effectiveness are helpful adjuncts to decision making, but that their conclusions depend on many assumptions. Ultimately, clinician judgment regarding their clinical benefit, balanced by some estimation of cost, may be more productive to target the right patients for whom the benefits can be well-justified.
| A BRIEF HISTORY OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE CAUSATION
To fully grasp the current debate regarding valuation of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mabs), one must appreciate the history of low-density lipoprotein cholesterol (LDL-C). Cholesterol was discovered over 200 years ago, but it was not until 1913 that a Russian medical student, Nikolai Anitschkow, demonstrated the association of cholesterol and atherosclerosis. 1 Twenty-six years later, Michael Macheboeuf identified distinct lipoproteins, but again the pathogenic/cholesterol connection lagged. 2 Then, in 1939, Carl Müller identified the first cases of familial hypercholesterolemia (FH), introducing genetics as a participant in cholesterol regulation. 3 His patients had extremely high cholesterol, fatty collections beneath their skin, and early onset heart disease.
The cholesterol-atherosclerosis link was bolstered. A decade later, in 1949, John Gofman took the cholesterol story to a more granular level by using analytic ultracentrifugation to separate disparate lipoprotein particles. 4 One was low-density lipoprotein (LDL). Gofman did not stop there; he demonstrated that patients with FH had not just high cholesterol levels, but more precisely, extremely elevated LDL-C. It was not until the 1960s that LDL-C became systematically studied. 5 The Framingham Heart Study, which started in 1948, was the first of such analyses. Subsequently, numerous other prospective cohort studies demonstrated concordant associations of LDL-C and atherosclerotic cardiovascular disease (ASCVD); the higher the LDL-C the more prevalent the ASCVD, whereas the lower the LDL-C, the less prevalent. These trials fueled more conclusive ones, the randomized controlled trials. The Scandinavian Simvastatin Survival Study, published in 1994, was a turning point for LDL's causal association with ASCVD. 6 In this placebo-controlled trial, over 5.4 years there was a compelling 30% relative risk reduction in cardiovascular (CV) mortality, an absolute 9% reduction (i.e., number needed to treat
[NNT] = 11) in the composite triple endpoint of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke, and a 30% reduction in all-cause mortality. The Cholesterol Treatment Trialists Collaboration (CTTC) meta-analysis of 26 trials documented that for every millimole per liter reduction in LDL-C, a consistent 22% relative risk reduction in ASCVD events followed, 8 which became the backbone of the American College of Cardiology (ACC)/American Heart Association (AHA) 2013 cholesterol guidelines. 9 Over the past decade, we have also seen a uniformity of results in Mendelian randomization studies evaluating LDL-C and ASCVD. 10 Consistently, mutations that cause high LDL-C result in a higher prevalence of ASCVD, whereas mutations causing low LDL-C result in the opposite. In 2017, the The stipulations for use required that eligible patients were taking maximally tolerated statin therapy yet still required additional lowering of LDL-C. On its face, these criteria seemed self-evident. What ensued proved otherwise.
Within the first 6 months following approval, denial rates for these medications were unprecedented, topping 80% in some analyses of claims. 25 The prior authorization (PA) and appeal processes were also exceptionally burdensome. A thorough evaluation of PCSK9 mabs claims and denials ensued. Evidence accrued illustrating flaws in the utilization management process, inconsistent adjudication, and a faulty initial review process. 26, 27 Perhaps most concerning of all were case reports in the New York Times, Reuters, Bloomberg, and the Wall Street Journal of incontrovertibly inappropriate PCSK9 mab denials. [28] [29] [30] [31] In response to such overwhelming evidence, the American Soci- clinicians, the media, and others were invited. A comprehensive paper was subsequently published, which defined the 5 central designations in the PCSK9 mab package inserts and produced simple, userfriendly, single page PA and appeal letters. 32 Clarifying and streamlining the process of prescribing these agents was the intent of this open-access paper and its attachments. To date, nearly 1000 clinicians have attended these town halls or utilized the consensus paper.
Still, access to PCSK9 mab remains problematic. Only when compared with placebo have statins shown a mortality benefit. To make a scientific claim about these partial mortality results of only 2-year plus analysis is not scientific. Additionally, the trial was not powered for mortality. It was too short to demonstrate a mortality benefit, and the confidence intervals for mortality were too large to infer any scientific conclusion. Most importantly, mortality cannot be the only endpoint that proves a drug's effectiveness. ICER also downplayed the importance of nonfatal MI and stroke.
| FOURIER AND THE NEW CV EVENT REDUCTION INDICATION
It is now recognized that reductions in nonfatal MI and stroke ultimately translate into downstream mortality benefits. Perhaps more important though is the fact that such events can result in not only life-altering morbidities for patients, they can also permanently adversely affect patients' relatives/caretakers. To reiterate, mortality cannot be the sole endpoint considered; other infirmities do evoke grave consequences. Finally, there is an irony in ICER's insistence that mortality reduction is a prerequisite to support the B+ rating that they refused to grant this drug class. Mortality could not be demonstrated in FOURIER in part because the trial was brief, its brevity being the consequence of an unexpectedly high residual ASCVD risk in the placebo arm. FOURIER thus proves that ASCVD patients need more intensive therapies because their residual risk remains unacceptably high. In a way, FOURIER's lack of a mortality benefit demonstrates just how important it is for appropriate high-risk patients to take the PCSK9 mabs.
The explanation for poor uptake of a PCSK9 mab was also distorted in the ICER report. 27 Others have studied large claims databases, demonstrating the lack of disparity in drug rejections among those on diverse statin regimens, with or without diabetes, and even with or without ASCVD (using prescription antiplatelet therapy as an ASCVD proxy). 26 The approval process, therefore, appears to be unpredictable. The FH foundation, ASPC, AACE, and others have published these findings in well-respected peer-reviewed journals. 32 A consistency of conclusions provides further credence to the claim that the process of drug approval/denial is seriously flawed.
| MODELING COST-EFFECTIVENESS OF MEDICATIONS
The purpose of economic models assessing drugs is to derive two A calculated ICER is compared to an "acceptable" ICER threshold to determine whether a novel therapy is worth its price tag. Unfortunately, this "acceptable" value is subjective; there is yet to be an agreed-upon number. In first world countries, WHO recommends 3 times of the GDP be used as the threshold. 39 For example, in the US, that is approximately $150,000, although the threshold can vary from $50,000 to $200,000. To better grasp an ICER's implications, one must examine the model itself, and the inputs used to draw conclusions on a therapy's cost effectiveness and in so doing, derive an ICER.
| REVIEW OF RECENT COST-EFFECTIVENESS MODELS OF PCSK9 INHIBITORS
There have recently been 2 models of cost-effectiveness of PCSK9 inhibitors published, with an update to 1 analysis. They differ greatly in their conclusions; 1 noted these agents would not be cost effective, whereas the other suggested they were close to current thresholds for acceptable cost-benefit.
The ICER analysis (Kazi et al.
42
) relied on the Coronary Heart Disease Policy Model published 30 years ago. 43 This is in contradistinction to the model employed by Fonarow et al., 44 which is based on Gandra et al., 45 Toth et al., 46 rates are uniformly lower (one-half to one-third) in clinical trials than in the real world. As the intent of these pharmacoeconomic models should be to determine whether PCSK9 mabs are cost effective outside of clinical trials and in the real world, it stands to reason that an optimal event rate should be real world. Event rates produce a large effect on a drug's value; low rates make it harder to demonstrate value whereas high rates do the opposite. Thus, the large disparity of event rates between these models is consequential. Inputting a spuriously low event rate diminishes the value of the medication under study.
| CHOOSING THE EVENTS THEMSELVES, ANOTHER POWERFUL PLAYER
In addition to selecting a given event rate to demonstrate treatment effect, the other substantial driver of model output, one must also In the end, we must return to clinical medicine, wherein we need to examine a drug's clinical benefit for an individual patient. The newer, more costly therapies should be targeted to those who will benefit most, and only after other less expensive therapies have failed to meet risk-reduction goals. Rather than using models to block access for all patients, payers should work jointly with clinicians, who can identify those patients who will benefit most. In so doing, we will assure the most cost-effective use of this important new class of drugs, and
